Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
Jan SielukJulia F SlejkoHenry SilvermanEleanor PerfettoC Daniel MullinsPublished in: Orphanet journal of rare diseases (2020)
Twelve months before and after their initial COPD diagnosis, patients with AATD incur higher healthcare utilization costs that are double the cost of similar COPD patients without AATD. This study also suggests that increased costs of AATD-associated COPD are not solely attributable to augmentation therapy use. Future studies should further explore the relationship between augmentation therapy, healthcare resource use, and other AATD-associated COPD expenditures.
Keyphrases
- chronic obstructive pulmonary disease
- healthcare
- lung function
- end stage renal disease
- ejection fraction
- newly diagnosed
- cystic fibrosis
- chronic kidney disease
- air pollution
- soft tissue
- mesenchymal stem cells
- health insurance
- patient reported outcomes
- current status
- cell therapy
- smoking cessation
- case control
- affordable care act